New AHA Statement on AI in Cardiovascular Imaging
Artificial intelligence has the potential to add value to cardiac imaging at every step of the patient journey, the AHA said in a new scientific statement.
Stay updated with breaking news from V Imaging. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Artificial intelligence has the potential to add value to cardiac imaging at every step of the patient journey, the AHA said in a new scientific statement.
New observational data suggested direct oral anticoagulants may be the optimal antithrombotic regime after transcatheter mitral valve replacement; randomized trials were needed.
The update includes new recommendations on temperature management and percutaneous coronary angiography in adults suffering cardiac arrest.
Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.
The Barostim neuromodulation system is now indicated in NYHA class III or class II HF despite guideline-directed medical therapies, with LVEF ≤ 35% and NT-proBNP < 1600 pg/mL.